Mortality Rates Among Substance Use Disorder Participants in Clinical Trials: Pooled Analysis of Twenty-Two Clinical Trials Within the National Drug Abuse Treatment Clinical Trials Network.
Most substance use disorders (SUD) treatment clinical trials are too short and small to reliably estimate the incidence of rare events like death.



The aim of this study is to estimate the overall mortality rates among a SUD treatment-seeking population by pooling participants from multiple clinical trials conducted through the National Institute on Drug Abuse (NIDA)-sponsored National Drug Abuse Treatment Clinical Trials Network (CTN).



Drug and or alcohol users (N=9866) who sought treatment and participated in one of the twenty-two CTN trials.



Data were collected through randomized clinical trials in national community treatment programs for SUD. Pooled analysis was performed to assess age- and gender-standardized mortality rate(s) (SM rate(s)), and mortality ratio(s) (SM ratio(s)) of CTN trial participants compared to the U.S. general population.



The age- and gender-SM rate among CTN trials participants was 1403 (95% CI: 862-2074) per 100,000 person years (PY) compared to 542 (95% CI: 541-543) per 100,000 PY among the U.S. general population in 2005. By gender, age-adjusted SM ratio for female CTN trial participants was over five times (SM ratio=5.35, 95% CI: 3.31-8.19)), and for male CTN trial participants, it was over three times (SM ratio=3.39, 95% CI: 2.25-4.90) higher than their gender comparable peers in the U.S. general population.



Age and gender-standardized mortality rates and ratios among NIDA CTN SUD treatment-seeking clinical trial participants are higher than the age and gender comparable U.S. general population. The overall mortality rates of CTN trial participants are similar to in-treatment mortality reported in large U.S. and non-U.S. cohorts of opioid users. Future analysis with additional CTN trial participants and risk times will improve the stability of estimates, especially within subgroups based on primary substance of abuse. These SUD mortality rates can be used to facilitate safety monitoring within SUD clinical trials.
The Emmes Corporation, Rockville, MD, United States.
Robert
R
Lindblad
The Emmes Corporation, Rockville, MD, United States.
Lian
L
Hu
The Emmes Corporation, Rockville, MD, United States.
Neal
N
Oden
Clinical Center, National Institutes of Health, Bethesda, MD, United States.
Paul
P
Wakim
Center for the Clinical Trials Network, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD, United States.
Carmen
C
Rosa
The Emmes Corporation, Rockville, MD, United States.
Paul
P
VanVeldhuisen
D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000592:standards / Q000706:statistics & numerical data*; D019966:Substance-Related Disorders / Q000401:mortality*
Clinical trial; Pooled analysis; Standardized mortality rate; Standardized mortality ratio; Substance use disorder
Drug Alcohol Depend. 2011 Apr 1;114(2-3):134-9
20971585
JAMA. 2001 Sep 26;286(12):1494-7
11572743
Med J Aust. 1999 Jul 5;171(1):34-7
10451670
Addict Behav. 2012 Apr;37(4):552-5
22209655
Am J Drug Alcohol Abuse. 1975;2(1):99-111
1190197
Drug Alcohol Depend. 2012 Jan 1;120(1-3):225-8
21752556
Clin Trials. 2010 Feb;7(1):58-68
20156957
Drug Alcohol Depend. 2011 Jun 1;115(3):190-5
21130585
Drug Alcohol Depend. 2005 Aug 1;79(2):137-43
16002023
Addiction. 2002 Jan;97(1):39-47
11895269
Drug Alcohol Depend. 2011 Jan 15;113(2-3):88-95
20828942
Am J Public Health. 1982 Jul;72(7):703-9
7091460
Am J Psychiatry. 2010 Jan;167(1):95-101
19917596
Drug Alcohol Depend. 2006 Feb 28;81(3):301-12
16169159
J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S87-96
20307800
J Subst Abuse Treat. 2013 Mar;44(3):309-15
22985677
Drug Alcohol Depend. 2012 Jan 1;120(1-3):55-64
21802222
Addiction. 2011 Jan;106(1):32-51
21054613
IARC Sci Publ. 1987;(82):1-406
3329634
J Chronic Dis. 1982;35(8):669-74
7096530
J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S14-30
20307792
Arch Gen Psychiatry. 2011 Dec;68(12):1238-46
22065255
JAMA. 2008 Nov 5;300(17):2003-11
18984887
Drug Alcohol Depend. 2008 Jan 1;92(1-3):200-7
17875368
J Nerv Ment Dis. 1980 Jan;168(1):26-33
7351540
J Clin Psychiatry. 2011 May;72(5):589-92
21536000
Eur Addict Res. 2003 Jan;9(1):18-28
12566794
J Subst Abuse Treat. 2009 Sep;37(2):138-50
19150206
Stat Med. 1997 Apr 15;16(7):791-801
9131766
J Subst Abuse Treat. 2010 Jun;38 Suppl 1:S4-13
20307794
J Epidemiol Community Health. 1984 Mar;38(1):85-8
6707569
Community Ment Health J. 2013 Dec;49(6):714-21
22843125
J Acquir Immune Defic Syndr. 2010 Sep;55(1):65-72
20393347
J Consult Clin Psychol. 2009 Aug;77(4):607-19
19634955
J Subst Abuse Treat. 2013 Jan;44(1):103-14
22657748
J Acquir Immune Defic Syndr. 2001 Dec 1;28(4):351-7
11707672
Clin Trials. 2005;2(3):209-17
16279144